Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Voriconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 17/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 11/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 11/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | CYP3A5 | P20815 | 1/20 | 1.00 |
| ▸ | CYP3A7 | P24462 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 1.00 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Voriconazole SCHEMBL29449338 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL28720611 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL29449336 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL824156 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL29378592 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL29449335 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL371715 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL3949267 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL4709722 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 | |
| Voriconazole SCHEMBL3713297 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2C19LMNACYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057699-B | Preparation method of voriconazole intermediate in-vitro racemate | 西安丽彩医药研发有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-114057699-A | Preparation method of voriconazole intermediate raceme | 陕西丽彩药业有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-103251565-A | Voriconazole freeze-dried powder injection for injection and preparation method thereof | ZHUHAI EBANG PHARMACEUTICAL CO LTD | 2013-08-21 | — | — | CN | claimed |
| US-20110312977-A1 | PROCESS FOR THE PREPARATION OF VORICONAZOLE | GLENMARK GENERICS LIMITED (IN) | 2011-12-22 | — | — | US | claimed |
| WO-2011045807-A2 | A NOVEL PROCESS TO MANUFACTURE (2R,3S)-2-(2,4-DIFLUOROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2,4-TRIAZOL-1-YL)BUTAN-2-OL | NEULAND LABORATORIES LTD. (IN) | 2011-04-21 | — | — | WO | claimed |
| WO-2010095145-A1 | PROCESS FOR THE PREPARATION OF VORICONAZOLE | GLENMARK GENERICS LIMITED (IN) | 2010-08-26 | — | — | WO | claimed |
| WO-2009084029-A2 | IMPROVED PROCESS FOR THE PREPARATION OF (2R,3S)-2-(2,4- DIFLUQROPHENYL)-3-(5-FLUOROPYRIMIDIN-4-YL)-1-(1H-1,2,4-TRIAZOL-1-YL) BUTAN-2-OL | NEULAND LABORATORIES LTD (IN) | 2009-07-09 | — | — | WO | claimed |
| US-7193083-B2 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | PFIZER, INC. (US) | 2007-03-20 | — | — | US | claimed |
| US-20050272747-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | PFIZER INC | 2005-12-08 | — | — | US | claimed |
| EP-0871625-B1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | PFIZER RES ANDDEVELOPMENT COMP (IE) | 2003-12-17 | — | — | EP | claimed |
| US-20030181720-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | BUTTERS MICHAEL (GB) | 2003-09-25 | — | — | US | claimed |
| EP-0871625-A1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-10-21 | — | — | EP | claimed |
| WO-1997006160-A1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-02-20 | — | — | WO | claimed |
| US-5567817-A | Triazole antifungal agents | PFIZER INC. (US) | 1996-10-22 | — | — | US | claimed |
| CN-118164968-A | Synthesis method of triazole antifungal drug voriconazole | 四川大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-114057699-B | Preparation method of voriconazole intermediate in-vitro racemate | 西安丽彩医药研发有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-114057699-B | Preparation method of voriconazole intermediate in-vitro racemate | 西安丽彩医药研发有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-5278175-A | Halopyridyl fungicides | PFIZER INC. (US) | 1994-01-11 | — | — | US | disclosed |
| EP-0440372-B1 | TRIAZOLE ANTIFUNGAL AGENTS | Pfizer Limited (GB) | 1993-06-02 | — | — | EP | disclosed |
| EP-0440372-A1 | Triazole antifungal agents | Pfizer Limited (GB) | 1991-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181720-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | IKZF2, SLC39A11, IKZF3 | CYP3A4 169/4885CYP2C9 624/4885CYP2C19 551/4885 |
| US-20110312977-A1 | PROCESS FOR THE PREPARATION OF VORICONAZOLE | CYP3A43, CYP3A4, CYP3A5 | CYP3A4 2/4885CYP2C9 10/4885CYP2C19 6/4885 |
| US-20050272747-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | SLC39A11, IKZF2, IKZF3 | CYP3A4 149/4885CYP2C9 476/4885CYP2C19 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.